ADDvise Group’s nomination committee for the Annual General Meeting 2023

14-10-2022   Regulatory press release

In accordance with the resolution at the 2022 annual general meeting of ADDvise Group, the nomination committee for the annual general meeting 2023 shall compose of representatives of the three largest shareholders by votes, according to the shareholders’ register maintained by Euroclear Sweden as of 30 June 2022, and the chairman of the board of directors. The representative appointed by the largest shareholder by votes shall be appointed chairman of the nomination committee.

The nomination committee has now been appointed and consists of the following members:

  • Per-Anders Tammerlöv (chairman of the nomination committee), representative of the shareholder Rikard Akhtarzand
  • Per Åhlgren, representative of the shareholder Gomobile nu AB
  • Roger Lindqvist, representative of the shareholder Caracal AB
  • Staffan Torstensson, chairman of board of ADDvise Group AB

The nomination committee shall prepare proposals for the 2023 annual general meeting regarding chairman of the meeting, chairman and members of the board of directors and remuneration to the directors of the board, committees and the auditor.

Shareholders can submit proposals to the nomination committee for the 2023 annual general meeting no later than 31 January 2023 by post to: ADDvise Group AB, att: Nomination Committee, Grev Turegatan 30, SE-114 38 Stockholm.

The Annual General Meeting 2023 in ADDvise Group AB will be held on May 5, 2023.
 

For further information, please contact:

Hanna Myhrman, General Counsel
+46 709 82 92 23
hanna.myhrman@addvisegroup.se



About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business - both geographically and product-wise. ADDvise Group's shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

ADDvise acquires CliniChain Holding B.V.

Regulatory

ADDvise Group AB has today entered into a share purchase agreement with the owners of CliniChain Holding B.V. (“CliniChain”) regarding the acquisition of all the outstanding shares of CliniChain in accordance with the letter of intent communicated via a press release dated September 6, 2022. Closing of the acquisition takes place no later than December…

ADDvise receives order worth USD 1.7 million

Regulatory

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from BioGeneric Pharma, a leading factory in biotechnology based in Cairo, Egypt. The order is worth approximately USD 1.7 million. The order is an add-on-project in the ongoing project between the parties regarding design, supply, and commissioning of clean room environment to be used…

ADDvise Group successfully places subsequent senior secured bonds of SEK 150 million at par

Regulatory

ADDvise Group AB (publ) ("ADDvise" or the "Company") announces today that the Company has successfully placed a subsequent senior secured bond issue (the “Subsequent Bond Issue") in an amount of SEK 150 million under the Company’s existing senior secured bond framework with ISIN SE0015222088. Following completion of the Subsequent Bond Issue, the outstanding amount under…